Tirzepatide (4 x 15mg Vial)

Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways. It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability). It also acts on appetite/satiety centres, contributing to reduced food intake.

This product is supplied as a pack of 4 vials, each containing 15 mg.

Key Benefits

  • Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).

  • Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.

  • Cardiometabolic improvements associated with weight loss and incretin pathway activity.

  • Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).

SKU:

Category:

Tags:

Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways. It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability). It also acts on appetite/satiety centres, contributing to reduced food intake.

This product is supplied as a pack of 4 vials, each containing 15 mg.

Key Benefits

  • Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).

  • Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.

  • Cardiometabolic improvements associated with weight loss and incretin pathway activity.

  • Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).

Technical Details

Part Number

Item Weight

Product Dimensions

Item model number

Item Package Quantity

Number of Handles

Batteries Required?

RECONSTITUTION, DOSING AND STORAGE OF PEPTIDES IN A VIAL
(General guidance – not peptide-specific)

1. INTRODUCTION
Peptides supplied in a vial (a glass vial containing lyophilised powder) are not ready for immediate use.
Before administration, it is mandatory to carry out reconstitution, which is the process of converting the lyophilised powder into a sterile liquid solution.
Correct reconstitution is essential to ensure:
Safe use
Peptide stability
Accurate dosing
Protocol effectiveness
⚠️ Incorrect preparation may result in inaccurate dosing and reduced effectiveness.

2. REQUIRED MATERIALS
Vial containing the lyophilised peptide
Bacteriostatic Water
    Contains approximately 0.9% benzyl alcohol
    Helps inhibit bacterial growth
Insulin syringe (100 units = 1 mL)
Sterile needle
Clean, hygienic environment

3. WHAT RECONSTITUTION IS
Reconstitution is the controlled addition of bacteriostatic water to the lyophilised powder, creating a liquid solution suitable for subcutaneous use.

4. GENERAL RULE FOR CALCULATING CONCENTRATION
Basic formula:
Amount of peptide (mg) ÷ Volume of water (mL) = Concentration (mg/mL)
This concentration is used to calculate the correct dose in the syringe.

5. CORRECT RECONSTITUTION TECHNIQUE
⚠️ IMPORTANT: PEPTIDES ARE FRAGILE MOLECULES
Recommended procedure:

  1. Draw the desired volume of bacteriostatic water into the syringe.
  2. Insert the needle into the vial.
  3. Allow the water to run slowly down the inner wall of the vial.
  4. Do not direct the stream straight onto the powder.
  5. Do not shake the vial.

Gently roll the vial between your fingers until fully dissolved.
**Vigorous shaking may cause peptide degradation.

6. CONVERSION FOR AN INSULIN SYRINGE
 1 mL = 100 units
The amount of peptide per unit depends on the final concentration after reconstitution.
Always calculate dosing based on the concentration (mg/mL).

7. STORAGE AFTER RECONSTITUTION
Keep refrigerated between 2°C and 8°C
Do not freeze
Keep the vial tightly sealed
Protect from light, especially for photosensitive peptides

8. FINAL CONSIDERATIONS

  • Always follow the correct preparation technique
  • Use bacteriostatic water only
  • Maintain strict accuracy in dose calculations
  • Use should be carried out under professional supervision

 

SURMOUNT-1 (NEJM, 2022 | Phase 3): over 72 weeks, mean weight loss of −15.0%, −19.5%, and −20.9% (5/10/15 mg), with cardiometabolic benefits and gastrointestinal events predominantly mild to moderate.

Standard Reconstitution (more practical)

Add 1.5 mL of diluent to a 15 mg vial.

Final concentration:
15 mg ÷ 1.5 mL = 10 mg/mL

Practical conversion:

  • 0.1 mL = 1 mg

  • 0.25 mL = 2.5 mg

  • 0.5 mL = 5 mg

  • 0.75 mL = 7.5 mg

  • 1.0 mL = 10 mg

This dilution makes weekly titration easier.

CLINICAL DOSING USED IN STUDIES

Based on published clinical protocols for Thera/ Tirzepatide:

Dose Escalation (Titration Schedule)

Week Weekly Dose
1–4 2.5 mg
5–8 5 mg
9–12 7.5 mg
13–16 10 mg
17+ 12.5 mg or 15 mg

Gradual titration is used to improve gastrointestinal tolerability.

Related Products

Retatrutide (4 x 10mg Vial)

Tirzepatide (4 x 15mg Vial)

Tirzepatide (60mg)

Retatrutide (40mg)